Biocon Biologics valued at $3.5 billion after Tata Capital's $30 million financing

Through investments in R&D and high-quality manufacturing infrastructure, we are confident of achieving our aspiration of serving 5 million patients through our biosimilars portfolio, CEO Hamachar said